AtaiBeckley (ATAI) Q4 2025 earnings summary

Executive summary

• Initiated pivotal Phase 3 program for BPL-003 in treatment-resistant depression, with FDA support and launch on track for Q2 2026.

• Reported positive Phase 2a results for EMP-01 in social anxiety disorder, meeting safety and efficacy endpoints.

• Completed strategic combination of atai Life Sciences and Beckley Psytech, and redomiciled to the U.S. as a Delaware corporation.

• Cash runway expected through early 2029, supporting planned topline readouts from both Phase 3 pivotal studies.

Financial highlights

• Cash, cash equivalents, and short-term securities totaled $220.7 million as of December 31, 2025, up from $72.3 million a year prior, driven by $291.1 million in net equity proceeds.

• R&D expenses were $53.1 million for 2025, down $2.4 million year-over-year due to lower personnel and consulting costs.

• G&A expenses rose to $65.1 million in 2025, up $17.6 million year-over-year, mainly from legal and professional fees related to the merger and redomiciliation.

• Net loss attributable to stockholders was $660.0 million for 2025, compared to $149.3 million in 2024, including $530.0 million in non-cash acquisition of in-process R&D expenses.

• Weighted average shares outstanding increased to 226.5 million in 2025 from 160.2 million in 2024.

Outlook and guidance

• Phase 3 BPL-003 program initiation remains on track for Q2 2026, with topline data from both pivotal studies expected by early 2029.

• VLS-01 Phase 2 Elumina trial topline data anticipated in H2 2026.

• Initial data from BPL-003 Phase 2a Part 4 cohort expected in Q4 2026.

• Cash position expected to fund operations into 2029.